<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='169'><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Patients>1736</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="203343"/><TrialStartDate>AUGUST   , 25, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>MMR-II; PUVV</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1551</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>1551</Patients><ProtocolAcronym/><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Reference>2009_667; NCT00986232; V221-011</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="60684"/><TrialStartDate>APRIL    , 30, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Patients>822</Patients><ProtocolAcronym/><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Reference>2009_666; NCT00984295; V221-013</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="60653"/><TrialStartDate>JUNE     , 30, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Patients>4011</Patients><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88475"/><TrialStartDate>JUNE     , 21, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Patients>1128</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Reference>MTA44; NCT00384397</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9949"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>1439</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>1439</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Reference>104020; 2004-005123-18; MeMuRu-OKA 043; NCT00126997</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11389"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Patients>5016</Patients><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94105"/><TrialStartDate>NOVEMBER , 09, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>752</EnrollmentCount><Interventions>Varivax</Interventions><Patients>752</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Reference>EudraCT#2004_002586_21; NCT00432523; V205-011; X04-MMRr-301</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="11525"/><TrialStartDate>JANUARY  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>MMR-II; PUVV</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1551</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>1551</Patients><ProtocolAcronym/><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Reference>2009_667; NCT00986232; V221-011</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="60684"/><TrialStartDate>APRIL    , 30, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56585">Vaxelis</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Patients>200</Patients><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference><Sponsor>Health Protection Agency</Sponsor><Trial id="132011"/><TrialStartDate>FEBRUARY , 01, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Patients>4538</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="91153"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EnrollmentCount>1560</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz; Priorix</Interventions><Patients>1560</Patients><ProtocolAcronym/><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Reference>ASCLIN/002/2013; NCT01991899</Reference><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><Trial id="161697"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="6621">Havrix</Drug><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Patients>1736</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="203343"/><TrialStartDate>AUGUST   , 25, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17674">Infanrix Quinta</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84867">Vaxem HIB</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Reference>2006-003476-35; NCT00488683; V59P16</Reference><Sponsor>Novartis AG</Sponsor><Trial id="10223"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="99518">JVC-001</Drug><EnrollmentCount/><Interventions>JVC-001</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Non-blind, randomized trial to evaluate the safety and immunogenicity of JVC-001 intended for Japanese healthy children</ProtocolTitle><Reference>JapicCTI-153031</Reference><Sponsor>Japan Vaccine Co Ltd</Sponsor><Trial id="244020"/><TrialStartDate>OCTOBER  , 05, 2015</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Anti-Chikungunya virus antibodies; Anti-Measles antibodies; Mononuclear leukocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="75100">MV-CHIK</Drug><EnrollmentCount>263</EnrollmentCount><Interventions>MV-CHIK; MV-CHIK; Priorix</Interventions><Patients>263</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Reference>2015-004037-26; MV-CHIK-202; NCT02861586</Reference><Sponsor>Themis Bioscience GmbH</Sponsor><Trial id="268409"/><TrialStartDate>AUGUST   , 17, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3263">Vaqta</Drug><EnrollmentCount>1800</EnrollmentCount><Interventions>ProQuad; Vaqta</Interventions><Patients>1800</Patients><ProtocolAcronym/><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Reference>2006_023; NCT00326183; V251-066</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="11511"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55366">Nimenrix</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>996</EnrollmentCount><Interventions>Priorix</Interventions><Patients>869</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Reference>115231; 2011-003672-36; 209762; MMR-159; NCT02058563</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="172270"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Patients>4538</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="91153"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Infanrix hexa; ProQuad</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17821">Infanrix HeXa</Drug><EnrollmentCount>955</EnrollmentCount><Interventions>Infanrix hexa; ProQuad</Interventions><Patients>955</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Reference>2006-004129-27; NCT00432042; V221-035; X06-MMRV-302</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="10599"/><TrialStartDate>JANUARY  , 12, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Patients>1783</Patients><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11526"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Reference>04-073; NCT00258726</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="11515"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Patients>3340</Patients><ProtocolAcronym/><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference><Sponsor>Sanofi Pasteur Inc</Sponsor><Trial id="77052"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><EnrollmentCount>218</EnrollmentCount><Interventions>trimethoprim + sulfamethoxazole</Interventions><Patients>218</Patients><ProtocolAcronym/><ProtocolTitle>A Phase III Study Of Prophylactic Antibiotics in Measles</ProtocolTitle><Reference>NCT00168532; ProfAnt-BHP-1996</Reference><Sponsor>Bandim Health Project</Sponsor><Trial id="11380"/><TrialStartDate>JANUARY  , 31, 1998</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Patients>4011</Patients><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88475"/><TrialStartDate>JUNE     , 21, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55366">Nimenrix</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Patients>1000</Patients><ProtocolAcronym/><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Reference>109670; NCT00474266</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9859"/><TrialStartDate>JUNE     , 05, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>74</EnrollmentCount><Interventions>ROR Vax</Interventions><Patients>74</Patients><ProtocolAcronym/><ProtocolTitle>Measles, Mumps, and Rubella (MMR) Immunity in College Students</ProtocolTitle><Reference>IRB00007373; NCT00962819</Reference><Sponsor>Emory University</Sponsor><Trial id="59758"/><TrialStartDate>MARCH    , 31, 2010</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Patients>4011</Patients><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88475"/><TrialStartDate>JUNE     , 21, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Patients>1736</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="203343"/><TrialStartDate>AUGUST   , 25, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Patients>458</Patients><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="102759"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EnrollmentCount>4050</EnrollmentCount><Interventions>measles vaccine (inhaled aerosol), WHO</Interventions><Patients>4050</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso</ProtocolTitle><Reference>NCT01668745; OPTIMUNISE_NOUNA_EARLY MV</Reference><Sponsor>Bandim Health Project</Sponsor><Trial id="200688"/><TrialStartDate>MAY      , 31, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="6621">Havrix</Drug><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Patients>5016</Patients><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94105"/><TrialStartDate>NOVEMBER , 09, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30214">diphtheria/tetanus/pertussis vaccine, sanofi pasteur</Drug><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Patients>3340</Patients><ProtocolAcronym/><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference><Sponsor>Sanofi Pasteur Inc</Sponsor><Trial id="77052"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="22877">RotaTeq</Drug><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Patients>2475</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Reference>MET42; NCT03537508</Reference><Sponsor>Sanofi Pasteur</Sponsor><Trial id="340960"/><TrialStartDate>APRIL    , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6621">Havrix</Drug><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Patients>1220</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79465"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="102979">quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Drug><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Patients>2475</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Reference>MET42; NCT03537508</Reference><Sponsor>Sanofi Pasteur</Sponsor><Trial id="340960"/><TrialStartDate>APRIL    , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Adacel; Priorix</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Diphtherinum; Morbilinum; Ourlianum; Pertussinum; Tetanotxicum</Interventions><Patients>150</Patients><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Reference>HVT; HVT-2016; NCT02825368</Reference><Sponsor>McMaster University</Sponsor><Trial id="265194"/><TrialStartDate>SEPTEMBER, 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Patients>1378</Patients><ProtocolAcronym/><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Reference>MTA48; NCT00483574</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9965"/><TrialStartDate>MAY      , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Reference>04-073; NCT00258726</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="11515"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Patients>1128</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Reference>MTA44; NCT00384397</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9949"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105909; 2005-005825-75; NCT00352898</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="187831"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>559</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>559</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Reference>103388; MMRV-042; NCT00127010</Reference><Sponsor>GlaxoSmithKline Biologicals</Sponsor><Trial id="11387"/><TrialStartDate>NOVEMBER , 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="9474">Varilrix</Drug><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Patients>5803</Patients><ProtocolAcronym/><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11418"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>330</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>330</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes</ProtocolTitle><Reference>106670; EudraCT: 2005-005944-22; NCT00351923</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11963"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="22877">RotaTeq</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Reference>2006-003476-35; NCT00488683; V59P16</Reference><Sponsor>Novartis AG</Sponsor><Trial id="10223"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Priorix</Interventions><Patients>150</Patients><ProtocolAcronym/><ProtocolTitle>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore</ProtocolTitle><Reference>209762/147; NCT00388440</Reference><Sponsor>GlaxoSmithKline Biologicals</Sponsor><Trial id="11425"/><TrialStartDate>NOVEMBER , 30, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EnrollmentCount>3750</EnrollmentCount><Interventions>measles vaccine (inhaled aerosol), WHO</Interventions><Patients>8309</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality</ProtocolTitle><Reference>NCT01644721; OPTIMUNISE_BHP_EARLY MV</Reference><Sponsor>Bandim Health Project</Sponsor><Trial id="198691"/><TrialStartDate>JULY     , 31, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59852">Pentaxim</Drug><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Patients>2475</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Reference>MET42; NCT03537508</Reference><Sponsor>Sanofi Pasteur</Sponsor><Trial id="340960"/><TrialStartDate>APRIL    , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Adacel; Priorix</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47199">Adacel</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>Diphtherinum; Morbilinum; Ourlianum; Pertussinum; Tetanotxicum</Interventions><Patients>150</Patients><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Reference>HVT; HVT-2016; NCT02825368</Reference><Sponsor>McMaster University</Sponsor><Trial id="265194"/><TrialStartDate>SEPTEMBER, 30, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>628</EnrollmentCount><Interventions>Priorix; SA-14-14-2</Interventions><Patients>628</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Reference>JEV06 (862058-1); NCT02880865</Reference><Sponsor>Path Inc</Sponsor><Trial id="269874"/><TrialStartDate>OCTOBER  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>405</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>405</Patients><ProtocolAcronym/><ProtocolTitle>ProQuad Intramuscular versus Subcutaneous</ProtocolTitle><Reference>2006-001986-40; F05-MMRV-304; NCT00402831; V221-036</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="11634"/><TrialStartDate>OCTOBER  , 06, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Patients>1220</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79465"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>3388</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>3388</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of ProQuad rHA in Infants</ProtocolTitle><Reference>2007-002438-12; MRV01C; NCT00560755; V221-037</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="11426"/><TrialStartDate>OCTOBER  , 24, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Infanrix hexa; ProQuad</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>955</EnrollmentCount><Interventions>Infanrix hexa; ProQuad</Interventions><Patients>955</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Reference>2006-004129-27; NCT00432042; V221-035; X06-MMRV-302</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="10599"/><TrialStartDate>JANUARY  , 12, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="56585">Vaxelis</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Patients>1220</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79465"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Patients>3340</Patients><ProtocolAcronym/><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference><Sponsor>Sanofi Pasteur Inc</Sponsor><Trial id="77052"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Patients>1664</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Reference>MTA37; NCT00422292</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9967"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Patients>1736</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="203343"/><TrialStartDate>AUGUST   , 25, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Patients>1664</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Reference>MTA37; NCT00422292</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9967"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Patients>458</Patients><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="102759"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Patients>5803</Patients><ProtocolAcronym/><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11418"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Patients>450</Patients><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="60050"/><TrialStartDate>NOVEMBER , 09, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Patients>1783</Patients><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11526"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>996</EnrollmentCount><Interventions>Priorix</Interventions><Patients>869</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Reference>115231; 2011-003672-36; 209762; MMR-159; NCT02058563</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="172270"/><TrialStartDate>JULY     , 01, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>Priorix</Interventions><Patients>732</Patients><ProtocolAcronym/><ProtocolTitle>A Phase IV, Open, Multicentric, Post-marketing Surveillance Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals’ Live Attenuated Measles-Mumps-Rubella vaccine (Priorix) in Korean Subjects Administered According to the Prescribing Information</ProtocolTitle><Reference>209762-145 (MeMuRu-145)</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="172850"/><TrialStartDate>AUGUST   , 20, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Patients>5016</Patients><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94105"/><TrialStartDate>NOVEMBER , 09, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>1560</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz; Priorix</Interventions><Patients>1560</Patients><ProtocolAcronym/><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Reference>ASCLIN/002/2013; NCT01991899</Reference><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><Trial id="161697"/><TrialStartDate>FEBRUARY , 28, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>IgG</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><EnrollmentCount>100</EnrollmentCount><Interventions>MMR; NeisVac-C</Interventions><Patients>100</Patients><ProtocolAcronym/><ProtocolTitle>Immunological Effect of Early Extra MMR Immunization in Infants Between 6 and 12 Months of Age in an Outbreak Setting</ProtocolTitle><Reference>2013-003078-28; IIV-273</Reference><Sponsor>National Institute for Public Health and the Environment</Sponsor><Trial id="156178"/><TrialStartDate>AUGUST   , 22, 2013</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>716</EnrollmentCount><Interventions>Meningitec; Priorix-Tetra</Interventions><Patients>716</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Reference>115555; 115555MMRV-063; 2011-001608-37; MMRV-063; NCT01506193</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="83852"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>ROR Vax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>467</EnrollmentCount><Interventions>second-generation MMR vaccine, Berna</Interventions><Patients>467</Patients><ProtocolAcronym/><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Reference>PMID: 16371870</Reference><Sponsor>Crucell Switzerland AG</Sponsor><Trial id="17279"/><TrialStartDate>DECEMBER , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>ProQuad</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1412</EnrollmentCount><Interventions>M-M-R II</Interventions><Patients>1412</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Reference>2017-001443-13; NCT01536405; P20930; V221-027</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="184151"/><TrialStartDate>JUNE     , 05, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Patients>1736</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="203343"/><TrialStartDate>AUGUST   , 25, 2014</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="6621">Havrix</Drug><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Patients>1783</Patients><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11526"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Reference>2009_538; NCT00839917; V221-023</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="44865"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="14438">Avaxim</Drug><EnrollmentCount>470</EnrollmentCount><Interventions>Avaxim; Trimovax</Interventions><Patients>470</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</ProtocolTitle><Reference>2015-005192-24; HAF65; NCT00313950</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="11423"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="42065">Bexsero</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="101326">MV-NIS (lung cancer), Vyriad</Drug><EnrollmentCount>4</EnrollmentCount><Interventions>MV-NIS (lung cancer), Vyriad; atezolizumab</Interventions><Patients>4</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Reference>NCT02919449; VYR-MV1-101</Reference><Sponsor>Vyriad</Sponsor><Trial id="273428"/><TrialStartDate>AUGUST   , 03, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Patients>1000</Patients><ProtocolAcronym/><ProtocolTitle>A Post Licensure Clinical Trial to Assess the Safety and Tolerability of BE’s Measles-rubella Vaccine in 9 to 12 Months Old Healthy Infants in a Single-Dose</ProtocolTitle><Reference>BECT048/MRV-PIV/CTP-02; CTRI/2019/04/018683</Reference><Sponsor>Biological E Ltd</Sponsor><Trial id="378426"/><TrialStartDate>APRIL    , 30, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105909; 2005-005825-75; NCT00352898</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="187831"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="60890">SA-14-14-2</Drug><EnrollmentCount>628</EnrollmentCount><Interventions>Priorix; SA-14-14-2</Interventions><Patients>628</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Reference>JEV06 (862058-1); NCT02880865</Reference><Sponsor>Path Inc</Sponsor><Trial id="269874"/><TrialStartDate>OCTOBER  , 31, 2016</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Patients>1000</Patients><ProtocolAcronym/><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Reference>109670; NCT00474266</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9859"/><TrialStartDate>JUNE     , 05, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Patients>1783</Patients><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11526"/><TrialStartDate>NOVEMBER , 30, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Patients>5016</Patients><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94105"/><TrialStartDate>NOVEMBER , 09, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Patients>5803</Patients><ProtocolAcronym/><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="11418"/><TrialStartDate>SEPTEMBER, 30, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10593">Meningitec</Drug><EnrollmentCount>716</EnrollmentCount><Interventions>Meningitec; Priorix-Tetra</Interventions><Patients>716</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Reference>115555; 115555MMRV-063; 2011-001608-37; MMRV-063; NCT01506193</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="83852"/><TrialStartDate>FEBRUARY , 29, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>970</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11388"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti-Measles antibodies; Immunoglobulin G; serum anti-Measles IgG</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><EnrollmentCount>60</EnrollmentCount><Interventions>licensed subcutaneous measles vaccine; measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Interventions><Patients>60</Patients><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices</ProtocolTitle><Reference>CTRI/2012/02/002447; NCT01557699; PMV-001</Reference><Sponsor>Serum Institute of India Ltd</Sponsor><Trial id="85837"/><TrialStartDate>MARCH    , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>270</EnrollmentCount><Interventions>Attenuvax; MMR vaccine, Merck &amp; Co; MMR vaccine, Merck &amp; Co</Interventions><Patients>110</Patients><ProtocolAcronym/><ProtocolTitle>A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group</ProtocolTitle><Reference>11202; ACTG 225; NCT00000815</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="11384"/><TrialStartDate>NOVEMBER , 30, 1999</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Patients>105</Patients><ProtocolAcronym/><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Reference>04-073; NCT00258726</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="11515"/><TrialStartDate>OCTOBER  , 31, 2005</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Patients>458</Patients><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="102759"/><TrialStartDate>MARCH    , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti-Measles antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>measles vaccine (live, freeze-dried), Serum Institute of India Limited</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="97346">measles vaccine, Cadila Healthcare</Drug><EnrollmentCount>327</EnrollmentCount><Interventions>measles vaccine, Cadila healthcare</Interventions><Patients>327</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Study To Compare The Immune Response And Safety Of Measles Vaccine Manufactured By Cadila Healthcare Ltd, With Measles Vaccine Manufactured By Serum Institute Of India Ltd, In Children 9 to 12 Months Of Age</ProtocolTitle><Reference>14-05; CTRI/2015/05/005739</Reference><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><Trial id="229988"/><TrialStartDate>MAY      , 12, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Patients>1128</Patients><ProtocolAcronym/><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Reference>MTA44; NCT00384397</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9949"/><TrialStartDate>SEPTEMBER, 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>970</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11388"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Reference>2006-003476-35; NCT00488683; V59P16</Reference><Sponsor>Novartis AG</Sponsor><Trial id="10223"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="39031">Menveo</Drug><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Patients>2475</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Reference>MET42; NCT03537508</Reference><Sponsor>Sanofi Pasteur</Sponsor><Trial id="340960"/><TrialStartDate>APRIL    , 25, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Reference>2009_538; NCT00839917; V221-023</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="44865"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature; Glycoproteins</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>M-M-R II; Varivax</Interventions><Patients>600</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Reference>NCT03239873; V210-A03</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="307614"/><TrialStartDate>OCTOBER  , 17, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72699">atezolizumab</Drug><EnrollmentCount>4</EnrollmentCount><Interventions>MV-NIS (lung cancer), Vyriad; atezolizumab</Interventions><Patients>4</Patients><ProtocolAcronym/><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Reference>NCT02919449; VYR-MV1-101</Reference><Sponsor>Vyriad</Sponsor><Trial id="273428"/><TrialStartDate>AUGUST   , 03, 2017</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><EnrollmentCount>1960</EnrollmentCount><Interventions>Schwarz measles vaccine; measles vaccine (inhaled aerosol), WHO</Interventions><Patients>1960</Patients><ProtocolAcronym/><ProtocolTitle>Long-term Follow-up of Measles Antibodies</ProtocolTitle><Reference>LTAB-2288/2292-Twodose1; Lægevidenskabens Fremme-2292; NCT00168571; NOVO-2288</Reference><Sponsor>Bandim Health Project</Sponsor><Trial id="14946"/><TrialStartDate>MARCH    , 31, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls>SIIL’s MR-Vac</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Patients>600</Patients><ProtocolAcronym/><ProtocolTitle>A clinical trial to assess the safety and protective efficacy of Biological Es Measles-Rubella Vaccine in 9 to 12 months old Infants in India</ProtocolTitle><Reference>BECT036/MRV-PII/III/CTP-02; CTRI/2016/07/007109</Reference><Sponsor>Biological E Ltd</Sponsor><Trial id="266205"/><TrialStartDate>JULY     , 29, 2016</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Bio-Manguinhos/Fiocruz</Controls><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EnrollmentCount>432</EnrollmentCount><Interventions>double viral vaccine (measles and rubella), Bio-Manguinhos/Fiocruz</Interventions><Patients>432</Patients><ProtocolAcronym>BIOMR</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Reference>ASCLIN 002/2017; BIOMR; NCT03148990</Reference><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><Trial id="298150"/><TrialStartDate>NOVEMBER , 20, 2018</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="12813">Rotarix</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>MR-Vac; Stamaril; Vitamin A</Controls><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14289">malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Drug><EnrollmentCount>700</EnrollmentCount><Interventions>malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Interventions><Patients>700</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and safety of GSK Biologicals malaria vaccine given at 6,7.5 and 9 months of age coadministered with measles,rubella and yellow fever vaccines</ProtocolTitle><Reference>PACTR201602001483150</Reference><Sponsor>GlaxoSmithKline Biologicals</Sponsor><Trial id="261663"/><TrialStartDate>SEPTEMBER, 14, 2016</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>MR vaccine (Serum Institute of India)</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="113162">MRVAC</Drug><EnrollmentCount>756</EnrollmentCount><Interventions>MRVAC</Interventions><Patients>756</Patients><ProtocolAcronym/><ProtocolTitle>Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (phase III)</ProtocolTitle><Reference>MRVAC VX.2016.01; NCT03713359</Reference><Sponsor>POLYVAC</Sponsor><Trial id="357452"/><TrialStartDate>APRIL    , 30, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Patients>450</Patients><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="60050"/><TrialStartDate>NOVEMBER , 09, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Patients>312</Patients><ProtocolAcronym/><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><Trial id="124248"/><TrialStartDate>APRIL    , 30, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="49241">Quadracel</Drug><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Patients>3340</Patients><ProtocolAcronym/><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference><Sponsor>Sanofi Pasteur Inc</Sponsor><Trial id="77052"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1800</EnrollmentCount><Interventions>ProQuad; Vaqta</Interventions><Patients>1800</Patients><ProtocolAcronym/><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Reference>2006_023; NCT00326183; V251-066</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="11511"/><TrialStartDate>MARCH    , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>4</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1620</EnrollmentCount><Interventions>ProQuad; ProQuad (group 1); ProQuad (group 2); ProQuad (group 3)</Interventions><Patients>1620</Patients><ProtocolAcronym/><ProtocolTitle>Comparative Study of Immunogenicity and Safety of a two-dose Regimen of ProQuad Manufactured With rHA</ProtocolTitle><Reference>2007-002468-88; MRV02C; NCT00566527; V221-038</Reference><Sponsor>Merck Sharp &amp; Dohme Corp, Sanofi Pasteur MSD</Sponsor><Trial id="11632"/><TrialStartDate>NOVEMBER , 29, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1200</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>1200</Patients><ProtocolAcronym/><ProtocolTitle>Study to evaluate frozen versus refrigerated MMRV (combined Measles, Mumps, Rubella, and Varicella) investigational vaccine</ProtocolTitle><Reference>2004_076; NCT00092430</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="12456"/><TrialStartDate>SEPTEMBER, 30, 2002</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10530">Comvax</Drug><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Patients>822</Patients><ProtocolAcronym/><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Reference>2009_666; NCT00984295; V221-013</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="60653"/><TrialStartDate>JUNE     , 30, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix-Tetra</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17141">Priorix-Tetra</Drug><EnrollmentCount>501</EnrollmentCount><Interventions>208136 vaccine, new formulation</Interventions><Patients>498</Patients><ProtocolAcronym>MEMURU-OKA-049</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GSK Biologicals 208136 Vaccine Formulated With New Measles and Rubella Working Seeds</ProtocolTitle><Reference>108760; 2011-005881-38; MEMURU-OKA-049; MEMURU-OKA-049; NCT00892775</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="54026"/><TrialStartDate>JUNE     , 03, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Patients>450</Patients><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="60050"/><TrialStartDate>NOVEMBER , 09, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9474">Varilrix</Drug><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Patients>970</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="11388"/><TrialStartDate>MAY      , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR (GSK-TV), GlaxoSmithKline</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><EnrollmentCount>240</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz</Interventions><Patients>240</Patients><ProtocolAcronym>MMR</ProtocolAcronym><ProtocolTitle>Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single- Dose and Multidose Presentations</ProtocolTitle><Reference>Asclin 003/2012; MMR; NCT01777529</Reference><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><Trial id="106360"/><TrialStartDate>OCTOBER  , 31, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Patients>4538</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="91153"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Patients>400</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Reference>105909; 2005-005825-75; NCT00352898</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="187831"/><TrialStartDate>APRIL    , 30, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15298">Pentacel</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Reference>2006-003476-35; NCT00488683; V59P16</Reference><Sponsor>Novartis AG</Sponsor><Trial id="10223"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="115970">live-attenuated viral vaccine (sc, measles/rubella virus infection), Indian Immunologicals</Drug><EnrollmentCount>55</EnrollmentCount><Interventions>Measles and Rubella Vaccine (Live), HBI</Interventions><Patients>55</Patients><ProtocolAcronym/><ProtocolTitle>A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects</ProtocolTitle><Reference>CTRI/2019/04/018635; HBI/MR/I/2018/001.01.00 Version 01</Reference><Sponsor>Indian Immunologicals Ltd</Sponsor><Trial id="377732"/><TrialStartDate>APRIL    , 17, 2019</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="99042">double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Reference>ASCLIN 002/2014; NCT02196285</Reference><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><Trial id="206205"/><TrialStartDate>SEPTEMBER, 30, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Anti-Chikungunya virus antibodies; Anti-Measles antibodies; Mononuclear leukocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>263</EnrollmentCount><Interventions>MV-CHIK; MV-CHIK; Priorix</Interventions><Patients>263</Patients><ProtocolAcronym/><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Reference>2015-004037-26; MV-CHIK-202; NCT02861586</Reference><Sponsor>Themis Bioscience GmbH</Sponsor><Trial id="268409"/><TrialStartDate>AUGUST   , 17, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54328">MVA-mBN85B</Drug><EnrollmentCount>90</EnrollmentCount><Interventions>MVA mBN85B</Interventions><Patients>90</Patients><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years</ProtocolTitle><Reference>MEA-HFN-002; NCT00891007</Reference><Sponsor>Bavarian Nordic A/S</Sponsor><Trial id="59936"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>752</EnrollmentCount><Interventions>Varivax</Interventions><Patients>752</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Reference>EudraCT#2004_002586_21; NCT00432523; V205-011; X04-MMRr-301</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="11525"/><TrialStartDate>JANUARY  , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>6</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Patients>822</Patients><ProtocolAcronym/><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Reference>2009_666; NCT00984295; V221-013</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="60653"/><TrialStartDate>JUNE     , 30, 2000</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Patients>3340</Patients><ProtocolAcronym/><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference><Sponsor>Sanofi Pasteur Inc</Sponsor><Trial id="77052"/><TrialStartDate>APRIL    , 30, 2011</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10774">NeisVac-C</Drug><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Patients>284</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference><Sponsor>MCM Vaccine BV</Sponsor><Trial id="85664"/><TrialStartDate>MARCH    , 30, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Patients>1220</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79465"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="57017">Kinrix</Drug><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Patients>4011</Patients><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="88475"/><TrialStartDate>JUNE     , 21, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="83793">Trivivac</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Trivivac</Interventions><Patients>200</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants</ProtocolTitle><Reference>NCT01763268; Trivivac2012</Reference><Sponsor>Queen Sirikit National Institute of Child Health</Sponsor><Trial id="104131"/><TrialStartDate>SEPTEMBER, 30, 2012</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>3+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Patients>1220</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="79465"/><TrialStartDate>JUNE     , 30, 2009</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>ROR Vax</Controls><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="41069">second-generation MMR vaccine, Berna</Drug><EnrollmentCount>467</EnrollmentCount><Interventions>second-generation MMR vaccine, Berna</Interventions><Patients>467</Patients><ProtocolAcronym/><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Reference>PMID: 16371870</Reference><Sponsor>Crucell Switzerland AG</Sponsor><Trial id="17279"/><TrialStartDate>DECEMBER , 31, 2005</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>5</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Patients>5016</Patients><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="94105"/><TrialStartDate>NOVEMBER , 09, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="34281">Prevnar 13</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Patients>200</Patients><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference><Sponsor>Health Protection Agency</Sponsor><Trial id="132011"/><TrialStartDate>FEBRUARY , 01, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>5</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>5</Patients><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of ProQuad in Children 6 to 24 Months Being Evaluated for Solid Organ Transplant</ProtocolTitle><Reference>NCT02687763; PRO25854</Reference><Sponsor>Medical University of South Carolina</Sponsor><Trial id="254035"/><TrialStartDate>DECEMBER , 31, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Hydrocortisone; Immunoglobulin G; Immunoglobulin G/Immunoglobulin M ratio; Interleukin-1 beta; Interleukin-6; Pancreatic alpha-amylase; Tumor necrosis factor</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><EnrollmentCount>6500</EnrollmentCount><Interventions>M-M-RvaxPRO</Interventions><Patients>6500</Patients><ProtocolAcronym/><ProtocolTitle>MMR at 6 Months Trial</ProtocolTitle><Reference>2016-001901-18; LGS.MMR.01.2016.2022; NCT03780179</Reference><Sponsor>Danish National University Hospital, Rigshospitalet, Denmark</Sponsor><Trial id="364134"/><TrialStartDate>APRIL    , 15, 2019</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Body temperature; Glycoproteins</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>600</EnrollmentCount><Interventions>M-M-R II; Varivax</Interventions><Patients>600</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Reference>NCT03239873; V210-A03</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="307614"/><TrialStartDate>OCTOBER  , 17, 2017</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="95202">MRBEV</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>A phase-I study to evaluate the safety and tolerability of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children in a single-dose schedule</ProtocolTitle><Reference>BECT032/MRV-PI/CTP-02; CTRI/2015/11/006375</Reference><Sponsor>Biological E Ltd</Sponsor><Trial id="246741"/><TrialStartDate>NOVEMBER , 25, 2015</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti-Parotitis virus antibodies; B-lymphocytes; Immunoglobulin A; Immunoglobulin G; Memory B-Lymphocytes; Memory T-Lymphocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="89684">M-M-RvaxPRO</Drug><EnrollmentCount>150</EnrollmentCount><Interventions>M-M-RvaxPRO</Interventions><Patients>150</Patients><ProtocolAcronym>BMR-3</ProtocolAcronym><ProtocolTitle>Third MMR Vaccine Dose In Young Adults</ProtocolTitle><Reference>BMR-3; NL57282.094.16 IIV-291; NTR5911</Reference><Sponsor>National Institute for Public Health and the Environment</Sponsor><Trial id="270107"/><TrialStartDate>SEPTEMBER, 01, 2016</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="39031">Menveo</Drug><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Patients>216</Patients><ProtocolAcronym/><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Reference>2006-003476-35; NCT00488683; V59P16</Reference><Sponsor>Novartis AG</Sponsor><Trial id="10223"/><TrialStartDate>JULY     , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10593">Meningitec</Drug><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Patients>1000</Patients><ProtocolAcronym/><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Reference>109670; NCT00474266</Reference><Sponsor>GlaxoSmithKline plc</Sponsor><Trial id="9859"/><TrialStartDate>JUNE     , 05, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>Pneumovax 23; Prevnar</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Reference>10609; ACTG P1024; NCT00013871; P1024; PACTG 1024</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10810"/><TrialStartDate>MARCH    , 31, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="97994">MMRV vaccine, Zydus Cadila Healthcare</Drug><EnrollmentCount>24</EnrollmentCount><Interventions>MMRV vaccine, Zydus Cadila Healthcare</Interventions><Patients>24</Patients><ProtocolAcronym/><ProtocolTitle>To Assess the Safety and Tolerability of Measles, Mumps, Rubella and Varicella Vaccine (Live-Attenuated, Freeze-Dried) in Healthy Adult Male Human Subjects</ProtocolTitle><Reference>CTRI/2015/10/006291; MMRVC 1001</Reference><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><Trial id="243853"/><TrialStartDate>OCTOBER  , 30, 2015</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4144">Prevnar</Drug><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Patients>1378</Patients><ProtocolAcronym/><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Reference>MTA48; NCT00483574</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9965"/><TrialStartDate>MAY      , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>CD4</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7080">Pneumovax 23</Drug><EnrollmentCount>300</EnrollmentCount><Interventions>Pneumovax 23; Prevnar</Interventions><Patients>300</Patients><ProtocolAcronym/><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Reference>10609; ACTG P1024; NCT00013871; P1024; PACTG 1024</Reference><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><Trial id="10810"/><TrialStartDate>MARCH    , 31, 2001</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>ProQuad</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3643">M-M-R II</Drug><EnrollmentCount>1412</EnrollmentCount><Interventions>M-M-R II</Interventions><Patients>1412</Patients><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Reference>2017-001443-13; NCT01536405; P20930; V221-027</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="184151"/><TrialStartDate>JUNE     , 05, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><EnrollmentCount>500</EnrollmentCount><Interventions>Varivax</Interventions><Patients>507</Patients><ProtocolAcronym/><ProtocolTitle>Safety Study of a Refrigerator-Stable Formulation of Varivax</ProtocolTitle><Reference>2004-002669-19; NCT00432731; V210-061; X04-VAR-402</Reference><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><Trial id="11524"/><TrialStartDate>DECEMBER , 31, 2004</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Patients>4538</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="91153"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Patients>200</Patients><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference><Sponsor>Health Protection Agency</Sponsor><Trial id="132011"/><TrialStartDate>FEBRUARY , 01, 2013</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Immunoglobulin G; Immunoglobulin M</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>14</EnrollmentCount><Interventions>Priorix</Interventions><Patients>14</Patients><ProtocolAcronym>BREMEAVAC</ProtocolAcronym><ProtocolTitle>Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR</ProtocolTitle><Reference>2014-001538-28; BREMEAVAC; NCT02325310; P130930</Reference><Sponsor>Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire de Limoges</Sponsor><Trial id="218981"/><TrialStartDate>FEBRUARY , 04, 2015</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2+</ArmCount><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Patients>1378</Patients><ProtocolAcronym/><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Reference>MTA48; NCT00483574</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9965"/><TrialStartDate>MAY      , 31, 2007</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>3</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="30177">Menactra</Drug><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Patients>1664</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Reference>MTA37; NCT00422292</Reference><Sponsor>Sanofi SA</Sponsor><Trial id="9967"/><TrialStartDate>DECEMBER , 31, 2006</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="6621">Havrix</Drug><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Patients>4538</Patients><ProtocolAcronym/><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><Trial id="91153"/><TrialStartDate>OCTOBER  , 10, 2012</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>2</ArmCount><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47279">ProQuad</Drug><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Patients>30</Patients><ProtocolAcronym/><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Reference>2009_538; NCT00839917; V221-023</Reference><Sponsor>Merck &amp; Co Inc</Sponsor><Trial id="44865"/><TrialStartDate>FEBRUARY , 29, 2008</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11458">Menitorix</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><EnrollmentCount>873</EnrollmentCount><Interventions>measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Interventions><Patients>873</Patients><ProtocolAcronym/><ProtocolTitle>Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine</ProtocolTitle><Reference>BJCDCWJ201601; NCT03160820</Reference><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><Trial id="298801"/><TrialStartDate>MARCH    , 31, 2016</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><ArmCount>1+</ArmCount><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="11457">Priorix</Drug><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Patients>213</Patients><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><Trial id="233238"/><TrialStartDate>AUGUST   , 31, 2015</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><ArmCount>1</ArmCount><Biomarkers/><Condition>Measles virus infection</Condition><Controls/><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="60890">SA-14-14-2</Drug><EnrollmentCount>628</EnrollmentCount><Interventions>SA-14-14-2</Interventions><Patients>628</Patients><ProtocolAcronym/><ProtocolTitle>Evaluation of the immunogenicity and safety of Japanese encephalitis vaccine when given with measles-mumps-rubella vaccine</ProtocolTitle><Reference>2016-CT0360; JEV06; PHRR160822-001339</Reference><Sponsor>Path Inc, Syneos Health Inc</Sponsor><Trial id="268796"/><TrialStartDate>OCTOBER  , 01, 2016</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row></Rowset>